COMPOSITION FOR THE PREVENTION AND THE TREATMENT OF HELICOBACTER PYLORI INFECTION

• US 20100298244A1
• Filed: 10/23/2009
• Published: 11/25/2010
• Est. Priority Date: 05/21/2009
• Status: Abandoned Application

• Current Assignee: National Taiwan University (Government of The Republic of China)
• Original Assignee: National Taiwan University (Government of The Republic of China)
• Inventors: Wang, Teh-Hong, Shun, Chia-Tung, Yang, Jyh-Chin, Chien, Chiang-Ting
• Application Number:
  US12/604,635
• Publication Number:
  US 20100298244A1
• Time in Patent Office: Days
• US Class Current: 514/23
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 31/7012 Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid gluconic acid A61K31/191; ascorbic acid A61K31/375
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 31/04 Antibacterial agents

Abstract

The disclosed item is a composition comprising catechins and sialic acid to provide an effective prevention and treatment for Helicobacter Pylori infection. This composition inhibits growth of Helicobacter pylori, and can increase the antioxidant activity of gastric mucosal cells through reducing the production of O₂.⁻, H₂O₂ and NO, and decreasing the expression of inducible nitric oxide synthase (iNOS) in cells. The apoptotic damage of stomach caused by Helicobacter pylori was decreased through up-regulation of autophagy to enhance the defensive ability of gastric epithelial cells toward Helicobacter pylori. Therefore the composition can be used in the treatment or prevention on damages caused by Helicobacter pylori infection.

Claims

1. A composition for the prevention of Helicobacter pylori infection, comprising at least 0.128 wt % c catechin and its derivatives;

at least 0.032 wt % c sialic acid; and

water.

2. The composition according to claim 1, wherein the catechin derivatives is selected from the group consisting of epigallocatechin gallate (EGCG), epicatechin gallate (ECG), gallocatechin gallate (GCG), epicatechin (EC), epigallocatechin (EGC), gallocatechin (GC), and any combination thereof.

3. The composition according to claim 1, wherein the catechin is extracted from a tea extract.

4. The composition according to claim 3, wherein the tea extract is a decaffeinated green tea extract.

5. The composition according to claim 1, wherein the composition is applied in a stomach.

6. The composition according to claim 1, wherein the composition is for oral administration.

7. The composition according to claim 1, wherein the composition increases the antioxidant activity of a gastric mucosal cell through reducing the production of O₂.⁻

, H₂O₂ and NO, and decreasing the expression of inducible nitric oxide synthase (iNOS) in the normal cell.

8. A composition for the treatment of Helicobacter pylori infection, which comprises from 128 mg/L to 640 mg/L catechin or its derivatives;

from 32 mg/L to 160 mg/L sialic acid; and

water.

9. The composition according to claim 8, wherein the catechin derivatives is selected from the group consisting of epigallocatechin gallate (EGCG), epicatechin gallate (ECG), gallocatechin gallate (GCG), epicatechin (EC), epigallocatechin (EGC), gallocatechin (GC), and any combination thereof.

10. The composition according to claim 8, wherein the catechin is extracted from a tea extract.

11. The composition according to claim 10, wherein the tea extract is a decaffeinated green tea extract.

12. The composition according to claim 8, wherein the composition is applied in a gastric disease.

13. The composition according to claim 12, wherein the gastric disease is chronic active gastritis, peptic ulcers, gastric cancer, or gastric mucosa-associated lymphoid tissue lymphoma.

14. The composition according to claim 8, wherein the composition is for oral administration.

15. The composition according to claim 8, wherein the composition increases the antioxidant activity of an infected cell through reducing the production of O₂⁻

, H₂O₂ and NO, and decreasing the expression of inducible nitric oxide synthase (iNOS) in the infected cell.

16. The composition according to claim 8, wherein the composition reduces the damage of a stomach caused by Helicobacter pylori through up-regulation of autophagy and down-regulation of apoptosis.